Intrinsic and extrinsic cues regulate the behavior of hematopoietic stem cells (HSC) and protect them from exhaustion. Recent advances in microscopy, flow cytometry, and transgenic animal models have revolutionized our understanding of the niches for HSC (Morrison and Scadden, 2014) . Despite the identification of several niche HSC maintenance factors, only a few have been linked to specific cellular sources through promoter-specific Cre deletion or overexpression, and this represents an area of ongoing work. In this SnapShot, we focus on three components of the bone marrow: the vasculature, the endosteal zone, and the progeny of HSCs. In addition, we explore emerging evidence of their role in the context of HSC mobilization and malignancy.
The Vasculature
The bone marrow contains two specialized types of blood vessels. Arterioles run in close proximity to the endosteal surface and are accompanied by sympathetic nerve fibers ensheathed by nonmyelinating Schwann cells. These are of narrow caliber, are lined by Sca-1-and VEGFR2-expressing endothelial cells, and drain into sinusoids. HSC in periarteriolar position are reported to be more quiescent and adjacent to Nestin hi perivascular mesenchymal cells. Sinusoids are evenly distributed throughout the marrow and drain into a central vein. They are highly fenestrated and lined by VEGFR3-and VEGFR2-expressing endothelial cells. Abluminal mesenchymal cells are identifiable by expression of indicator genes from promoters for Nestin, LepR, Prx-1, or Mx-1, with overlaps between the populations not well defined. Expression of kitL and CXCL12 are important for maintenance and/or localization of HSC.
The Endosteal Zone
This region is particularly important in HSC engraftment post transplantion, and a number of studies have indicated preferential localization of HSC here under homeostasis. Periarteriolar HSCs in this zone have been reported to be more quiescent. Endosteal osteolineage cells (OLC) are regulators of lymphoid and myeloid progenitor cells and participate in HSC mobilization following agents such as G-CSF. This and other effects on HSC are likely to be indirect. Extracellular matrix proteins such as osteopontin and even ionic calcium abundant near bone participate in HSC activity and position. The bone marrow is hypoxic (<32 mM Hg) but is less so at the endosteum, as it is richly endowed with arterioles (Spencer et al., 2014) .
Mature Hematopoietic Cells
Bone marrow macrophages, and possibly osteoclasts, participate in HSC localization. Senescent neutrophils engulfed by resident macrophages appear to influence the macrophage effect on localization. Megakaryocytes are implicated in the regulation of HSC quiescence, and T-regulatory cells provide a relative immune sanctuary for HSC (Fujisaki et al., 2011) .
HSC Trafficking
HSC migrate from the bone marrow to the blood and back in a complex, still unresolved process that is critical for clinical stem cell transplantation. The localization of HSC to bone marrow is dependent on CXCL12, VCAM1, PSGL-1, and E/L selectin ligand, and mobilization can be induced by interruption of CXCR4 or VLA-4 and/or activation of CXCR2. It is regulated physiologically in a circadian manner and is responsive to inflammatory cytokines such as G-CSF (Motabi and DiPersio, 2012) .
The Niche in the Context of Hematologic Malignancy
Mesenchymal cells comprising the regulatory microenvironment for hematopoiesis are increasingly recognized as participants in the malignant process. Modification of "stroma" in genetically engineered mice is either sufficient for or cooperates with genetic lesion in hematopoietic cells to enable myeloproliferative neoplasia (MPN). Perturbing miRNA processing or ribosomal components in specific subsets of immature osteolineage cells can induce myelodysplasia and rarely results in acute myeloid leukemia (AML) (Raaijmakers et al., 2010) , whereas activation of β-catenin in more mature osteoblastic cells can induce AML with high penetrance via Notch activation (Kode et al., 2014) . This corresponds to findings in a substantial fraction of patient samples with AML (Kode et al., 2014) . Specific microenvironmental components, such as stromal cells and the sympathetic nervous system, may also be responsive to malignant cells with specific changes in cytokine expression that disadvantage normal hematopoietic cells and favor neoplastic cell outgrowth (Schepers et al., 2013; Arranz et al., 2014) . The environment further alters sensitivity of malignant cells to chemotherapy and may contribute to chemoresistance (Levesque et al., 2013) . However, ex vivo microenvironment-like additions to chemical screening for AML therapies may enable identification of novel potential therapeutics (Hartwell et al., 2013) 
